PureTech Health (LON:PRTC) Shares Up 9.1% - What's Next?

Key Points

• PureTech Health's stock price increased by 9.1% during trading, reaching a high of GBX 116.80 ($1.58) before closing at GBX 116.04 ($1.57).
• The company has a market capitalization of £283.50 million and a notably high price-to-earnings ratio of 690.00.
• Insider Bharatt Chowrira acquired 167,739 shares of PureTech Health at an average cost of GBX 1 per share, signaling confidence in the company's potential.

PureTech Health plc (LON:PRTC - Get Free Report) rose 9.1% during mid-day trading on Friday . The company traded as high as GBX 116.80 ($1.57) and last traded at GBX 116.04 ($1.56). Approximately 866,820 shares were traded during trading, an increase of 18% from the average daily volume of 736,782 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Performance

The firm has a market cap of £293.65 million, a price-to-earnings ratio of 714.71 and a beta of 1.02. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The business's 50-day simple moving average is GBX 129.46 and its two-hundred day simple moving average is GBX 129.76.

Insider Transactions at PureTech Health

In other news, insider Bharatt Chowrira acquired 167,739 shares of the business's stock in a transaction dated Thursday, July 3rd. The stock was acquired at an average price of GBX 1 per share, with a total value of £1,677.39. Insiders own 13.13% of the company's stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.